Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) changed 0.79% to recent value of $11.43. The stock transacted 506461 shares during most recent day however it has an average volume of 971.01K shares. It spotted trading -45.23% off 52-week high price. On the other end, the stock has been noted 21.08% away from the low price over the last 52-weeks.
Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced that it will present new analyses of efficacy and quality of life data from its clinical trials for eptinezumab at the American Headache Society’s (AHS) 61st Annual Scientific Meeting in Philadelphia, PA being held on July 11-14, 2019. Eptinezumab is an investigational monoclonal antibody delivered by IV administration. It was designed for 100% bioavailability with high specificity and strong binding for rapid, robust and sustained suppression of calcitonin gene-related peptide (CGRP).
At the meeting, more than a dozen presentations related to eptinezumab’s safety and efficacy of response in migraine prevention will be shared, including an analysis of 100% response rates for patients with episodic or chronic migraine who were treated with eptinezumab in the Phase 3 PROMISE-1 and PROMISE-2 clinical trials. Another key presentation will focus on the impact of eptinezumab on migraine severity and quality of life. Additional eptinezumab presentations at the meeting will feature a visual representation of the molecule’s binding properties and further analyses related to safety and quality of life data.
Dr. Paul Streck, chief medical officer of Alder said “We’re excited to share new data that reinforces eptinezumab as a significant migraine prevention treatment option that has the potential to help the millions of people with this debilitating and highly symptomatic disease,”. “We’ve previously presented data on eptinezumab’s efficacy and rapid onset of prevention benefit and these new analyses will show its impact in migraine-free months and improvements in severity and patient-reported outcomes in our clinical trials. We look forward to delivering this important treatment option early next year, if approved, to improve the lives of people living with migraine.”
The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) filing for eptinezumab in April 2019, and set a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020. If approved, eptinezumab will be the first-to-market IV therapy for migraine prevention.
ALDR . Its earnings per share (EPS) expected to touch remained 1.60% for this year while earning per share for the next 5-years is expected to reach at 23.46%.
The company has 80.17M of outstanding shares and 73.4M shares were floated in the market. According to the most recent quarter its current ratio was 8.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of -0.96% from the mean of 20 days, -1.31% from mean of 50 days SMA and performed -10.33% from mean of 200 days price. Company’s performance for the week was -3.38%, -5.15% for month and YTD performance remained 11.51%.
Daniel Johnson – Category – Finance
Daniel Johnson studied a business degree majoring in finance and security analysis. He has a deep understanding of both technical and fundamental forms of analysis, he deeply believes that it makes a lot more sense for average investors to understand fundamental analysis, which he believes anyone can learn. Daniel has over 10 years of experience as a professional journalist, writer and an editor. He holds a bachelor’s degree in International Business from University of Melbourne. He writes articles about hot stocks, dividend growth investing, options trading, investment decisions, stock selection, portfolio management, and passive income generation. Daniel also reports on Finance category.
Email Contact: Daniel@stockdigest.info
Address: 4487 Roger Street, Nanaimo, British Columbia
Zip Code: V9R 5H9
Phone Number: 250-760-7308